Participated · Series A · Jan 2025

Immunis is a clinical-stage biotechnology company developing stem cell‑derived, multi-active biologics using its multi-active secretome technology to deliver natural human immune modulators. Its lead investigational product, IMM01‑STEM, is being developed to address age-related muscle atrophy and metabolic dysfunction in elderly patients. A Phase 1/2a trial in nine elderly patients showed safety, tolerability and suggestive efficacy, including improvements in quality-of-life measures and gait speed. Preclinical studies in aged mouse models published in GeroScience and Aging Cell showed reversal of muscle atrophy, improved muscle function, enhanced metabolism and reduced body and liver fat. The company describes itself as the leading biotech with the most advanced stem cell‑derived multi-active biologic in human clinical trials. The recently closed financing will fund two Phase 2 clinical trials to further test IMM01‑STEM’s efficacy in targeted elderly populations. Immunis is a private biotech developing a novel immunomodulatory secretome product line (STEM) to address age- and disease-related immune decline. The STEM product line leverages stem cell technology to deliver all-natural, all-human immune modulators in their natural, relative physiological concentrations. Its lead secretome treatment, IMM01-STEM, is described as using natural immunomodulators with potent cytoskeletal remodeling properties. The company plans to use the new funding to support clinical assessment of IMM01-STEM in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy. The trial targets muscle atrophy, a condition the article states is experienced by 100% of the population in age, disuse, and disease contexts. Immunis is based in Irvine, California.

Participated · Series B · Dec 2022

Gilgamesh Pharmaceuticals pursues discovery and development of improved neuropsychiatric drugs, using a platform that combines neural-circuit translational methods with AI and machine learning to optimize safety, efficacy and dosing. Its pipeline includes the ibogaine-analog GM-3009 (supported by a $14 million NIDA grant), the oral NMDAR antagonist GM-1020 (completed Phase 1 SAD/MAD and progressed into Phase 2), non-hallucinogenic neuroplasticity candidates now in IND-enabling stages, and projects targeting M1/M4 receptors. In August 2025 the company completed a strategic divestiture of clinical-stage candidate GM-2505 to AbbVie for up to $1.2 billion, and it has a separate AbbVie collaboration that included a $65 million upfront payment and up to $1.95 billion in option/ milestone payments plus royalties. The company assembled a leadership team with extensive CNS drug-development experience and intends to use recent financing to fund clinical and preclinical programs and continued discovery efforts. Gilgamesh was founded in 2019 by Jonathan Sporn and Andrew Kruegel.

Participated · Seed · Apr 2022

Homecoming is a Toronto-based health-tech startup that offers a comprehensive patient care platform designed specifically for psychedelic therapy. The software supports clients before, between, and after psychedelic sessions with personalized guides, tasks, and daily check-ins. Clinics and retreats use the system to streamline operations, manage the entire patient experience, and reach more patients through modern therapy tools and precision data. By integrating preparation and integration support into one interface, the platform aims to improve clinical outcomes and operational efficiency. The company plans to use newly secured capital to scale its products and services, deepening its partnerships with psychedelic clinics and retreats. Although detailed user or revenue figures were not disclosed, management emphasizes its data-driven approach to enhancing patient engagement and care continuity.

Led · Seed · Feb 2022

Fluence is an expertise-driven educational platform that provides professional certification and training in psychedelic therapy and integration. Founded in 2019 and based in NYC, the company works directly with licensed healthcare professionals and graduate students to advance clinical skills and evidence-based psychedelic care. Over the past two years it has trained nearly 1,000 practitioners and has partnerships with drug developers including Beckley Psytech, Tryp Therapeutics, and Clairvoyant Therapeutics to develop therapy manuals and custom training for clinical trial therapists. Fluence plans to expand its course and certificate offerings and bolster development of training software and its e-learning platform. The company is also developing a psilocybin-assisted therapy program to meet Oregon Health Authority requirements ahead of Measure 109 implementation. Leadership includes founders Dr. Ingmar Gorman and Dr. Elizabeth Nielson and COO Michael Kuntz.

Participated · Seed · Jul 2021

Psilera is a biopharmaceutical company developing novel neuroplastogens and psychedelic-derived therapies, headquartered in Tampa, Fla. Its lead compound, PSIL-006, is described as a first-in-class neuroplastogen designed to capture therapeutic benefits of traditional psychedelics while minimizing hallucinogenic and cardiovascular effects. The company plans to advance PSIL-006 into first-in-human trials in 2027 and is using its recent financing to support that transition to clinical-stage development. Psilera has secured an NIH award of up to $2 million for IND-enabling studies in alcohol use disorder and executed a strategic licensing agreement with atai Life Sciences (now AtaiBeckley) for a DMT patent portfolio. Recent corporate developments include the appointment of Magali Haas, MD/PhD, as Chief Medical Officer as Psilera scales operations toward clinical milestones.